Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Chinese University of Hong Kong: Clinical Trials & FDA Approval Profile

Chinese University of Hong Kong (Global / Institutional) sponsors 75 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 41 active protocols (30 recruiting now), 19 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)5.3%
Median Closed Enrollment vs National (145 pts)40 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Chinese University of Hong Kong
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)75
Active Pipeline (Recruiting Now)41 (30)
Completed vs Stopped Early19 / 4 (5.3%)
Median Closed Actual Enrollment40 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Chinese University of Hong Kong
Hospital Research SiteLocationShared Protocols
Queen Mary HospitalHong Kong2

Explore interactive annual charts and M&A subsidiary rollups in the Chinese University of Hong Kong Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI